Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine (NE) cancer that accounts for approximately 15% of all lung cancer, with an annual incidence of more than 34,000 in the United State
This record provides details of the data supporting the claims of the related article: “How Can Artificial Intelligence Models Assist PD-L1 Expression Scoring in Breast Cancer: Results of Multi-instit
BackgroundPD-1/PD-L1 blockade is a promising immunotherapeutic strategy with the potential to improve the outcomes of various cancers. However, there is a critically unmet need for effective biomarker
